Replimune Group, Inc. (REPL)

NMS – Real vaqt narxi. Valyuta: USD

11.63

+0.50 (4.49%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

11.63

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 7:54 PM EDT

01.06.2026

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.

31.05.2026

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting.

30.05.2026

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.

30.05.2026

How Replimune's drug got a third chance after the White House intervened

Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.

29.05.2026

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune said it plans to resubmit its melanoma drug for approval following two earlier rejections. The move follows the departure of Food and Drug Administration Commissioner Marty Makary.

29.05.2026

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune said on Friday ‌it it has reached an agreement with the ⁠U.S. Food and Drug Administration to resubmit the marketing application for its ‌experimental ⁠skin cancer drug after the regulator ⁠twice declined to approve the ⁠therapy.

29.05.2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative communications with the U.S. Food and Drug Administration (FDA), the Company and the FDA have aligned on a path forward for resubmission and reconsideration of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.

Videolar

13.04.2026

Negative

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Press-relizlar

31.05.2026

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

30.05.2026

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

29.05.2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

21.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Replimune Group, Inc. (REPL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Replimune Group, Inc. (REPL)

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

How Replimune's drug got a third chance after the White House intervened

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Videolar

Press-relizlar

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

How Replimune's drug got a third chance after the White House intervened

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Videolar

Press-relizlar

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

Search stocks

Replimune Group, Inc. (REPL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Replimune Group, Inc. (REPL)

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

How Replimune's drug got a third chance after the White House intervened

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Videolar

Press-relizlar

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

How Replimune's drug got a third chance after the White House intervened

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Videolar

Press-relizlar

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL